As of 2025-10-25, the EV/EBITDA ratio of Cardiff Oncology Inc (CRDF) is -2.73. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Cardiff's latest enterprise value is 147.03 mil USD. Cardiff's TTM EBITDA according to its financial statements is -53.94 mil USD. Dividing these 2 quantities gives us the above Cardiff EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.1x - 13.6x | 13.2x |
| Forward P/E multiples | 14.0x - 29.2x | 15.4x |
| Fair Price | (11.35) - (10.99) | (11.59) |
| Upside | -613.6% - -597.5% | -624.6% |
| Date | EV/EBITDA |